# reload+after+2024-01-20 18:35:38.248415
address1§1 Francis Crick Avenue
address2§Cambridge Biomedical Campus
city§Cambridge
zip§CB2 0AA
country§United Kingdom
phone§44 20 3749 5000
website§https://www.astrazeneca.com
industry§Drug Manufacturers - General
industryKey§drug-manufacturers-general
industryDisp§Drug Manufacturers - General
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
fullTimeEmployees§83500
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Pascal  Soriot D.V.M., M.B.A.', 'age': 64, 'title': 'CEO & Executive Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 4780000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Aradhana  Sarin M.D.', 'age': 48, 'title': 'CFO & Executive Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 2735000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Pam P. Cheng', 'age': 52, 'title': 'EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew P. Barnett', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Pott', 'title': 'CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Gonzalo  Vina', 'title': 'Head of Global Media Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Menelas Nicolas  Pangalos Ph.D.', 'age': 55, 'title': 'EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ruud  Dobber Ph.D.', 'title': 'Executive Vice-President of BioPharmaceuticals Business Unit', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Susan Mary Galbraith M.D., Ph.D.', 'age': 57, 'title': 'Executive Vice President of Oncology Research & Development', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Leon  Wang', 'title': 'Executive VP of International & China President', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§2
compensationRisk§3
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§2.35
dividendYield§0.0218
exDividendDate§1691625600
payoutRatio§0.76089996
fiveYearAvgDividendYield§2.56
beta§0.159
priceToSalesTrailing12Months§3.7064102
currency§GBp
forwardEps§6.57
pegRatio§2.61
lastDividendValue§71.8
lastDividendDate§1691625600
exchange§LSE
quoteType§EQUITY
shortName§ASTRAZENECA PLC ORD SHS $0.25
longName§AstraZeneca PLC
firstTradeDateEpochUtc§737967600
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§27544b2d-307c-3184-8717-9e464471fcc0
messageBoardId§finmb_336774
targetHighPrice§170.14
targetLowPrice§65.22
targetMeanPrice§127.08
targetMedianPrice§124.87
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§23
quickRatio§0.599
earningsGrowth§-0.162
grossMargins§0.89169997
ebitdaMargins§0.41574
trailingPegRatio§0.5294
